Pacira | PCRX - Sales Revenues

Stock Price
20.91
Daily Change
0.55 2.70%
Monthly
-19.58%
Yearly
-19.89%
Q1 Forecast
19.91

Pacira reported $179.52M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Astellas Pharma JPY 571.21B 46.89B Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Ironwood Pharmaceuticals USD 122.06M 36.82M Sep/2025
J&J USD 24.6B 610M Dec/2025
Ligand Pharmaceuticals USD 115.46M 67.83M Sep/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Pacira USD 179.52M 1.58M Sep/2025
Perrigo USD 1.04B 16.3M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Supernus Pharmaceuticals USD 192.1M 26.6M Sep/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Xeris Pharmaceuticals USD 74.38M 2.84M Sep/2025
Zoetis USD 2.4B 60M Sep/2025